Vigil Neuroscience (NASDAQ:VIGL) Price Target Cut to $14.00 by Analysts at HC Wainwright

Vigil Neuroscience (NASDAQ:VIGL) had its target price trimmed by HC Wainwright from $17.00 to $14.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also recently commented on VIGL. William Blair began coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating on the stock. JMP Securities reissued a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Finally, Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $16.25.

Vigil Neuroscience Stock Performance

Vigil Neuroscience stock opened at $2.02 on Friday. The stock has a market cap of $82.58 million, a P/E ratio of -0.98 and a beta of 1.82. Vigil Neuroscience has a fifty-two week low of $1.49 and a fifty-two week high of $6.06. The firm’s fifty day moving average price is $2.34 and its 200-day moving average price is $2.79.

Vigil Neuroscience (NASDAQ:VIGL) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.08). Sell-side analysts predict that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Institutional Trading of Vigil Neuroscience

Institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC boosted its position in Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock valued at $41,000 after buying an additional 8,358 shares during the period. Jane Street Group LLC purchased a new stake in Vigil Neuroscience during the fourth quarter valued at about $83,000. Barclays PLC boosted its position in Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company’s stock valued at $109,000 after buying an additional 19,436 shares during the period. Northern Trust Corp boosted its position in Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock valued at $110,000 after buying an additional 14,572 shares during the period. Finally, Two Sigma Advisers LP boosted its position in Vigil Neuroscience by 243.8% during the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock valued at $117,000 after buying an additional 49,000 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.